Global Organ Care Products Market to Reach US$483.4 Million by 2030

The global market for Organ Care Products estimated at US$197.3 Million in the year 2024, is expected to reach US$483.4 Million by 2030, growing at a CAGR of 16.1% over the analysis period 2024-2030. Trolley Organ Care, one of the segments analyzed in the report, is expected to record a 17.6% CAGR and reach US$344.8 Million by the end of the analysis period. Growth in the Portable Organ Care segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$53.8 Million While China is Forecast to Grow at 21.6% CAGR

The Organ Care Products market in the U.S. is estimated at US$53.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$106.9 Million by the year 2030 trailing a CAGR of 21.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 14.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

Global Organ Care Products Market - Key Trends & Drivers Summarized

Why Are Organ Care Products Becoming Crucial to the Future of Transplantation Medicine?

Organ care products are playing a pivotal role in improving the outcomes, logistics, and reach of organ transplantation procedures by enabling organs to be preserved, assessed, and transported more efficiently than traditional cold storage methods. With global organ shortages and transplant waitlists growing rapidly, the focus has shifted from simply harvesting organs to optimizing their viability and function during the critical pre-implantation period. These advanced preservation technologies-which include ex vivo perfusion systems, portable organ preservation devices, and nutrient-rich transport solutions-have revolutionized organ handling for heart, lung, liver, and kidney transplants.

The clinical rationale behind organ care systems lies in minimizing ischemic injury during the transport window. Traditional static cold storage (SCS) only slows down metabolic decay; however, dynamic perfusion systems mimic physiological conditions by circulating oxygenated blood or preservation fluids through the organ. This not only extends preservation times but also enables real-time functional assessments, reduces discard rates, and expands the donor pool by including marginal or extended criteria organs.

The shift from reactive preservation to active perfusion and diagnostics is enhancing transplant success rates and patient survival. Technologies such as the TransMedics Organ Care System (OCS) and XVIVO perfusion platforms are allowing transplantation teams to make data-driven decisions about organ usability. As transplant centers aim to perform more out-of-region or donation-after-cardiac-death (DCD) procedures, organ care products are becoming a standard of care for high-risk and long-distance transport scenarios.

What Are the Key Innovations Enhancing Organ Preservation and Transport Capabilities?

Technological advancements in organ care are centered on enabling normothermic and hypothermic machine perfusion to improve graft quality and reduce ischemia-reperfusion injury. Normothermic perfusion systems keep organs at body temperature while providing oxygen, nutrients, and waste removal-allowing metabolism to continue, tissue healing to occur, and viability metrics to be recorded. For example, heart perfusion systems maintain myocardial contractility during transport, while liver perfusion enables bile production and lactate clearance as surrogate markers of organ health.

Advanced perfusion fluids, oxygenation membranes, and pressure-controlled circuits are improving the physiological mimicry and compatibility of these devices with different organs. Smart monitoring systems embedded with sensors allow continuous tracking of parameters such as flow rate, temperature, pH, oxygenation, and enzymatic markers. Machine learning algorithms are being tested to correlate real-time perfusion data with post-transplant outcomes, helping clinicians make more accurate go/no-go decisions.

Miniaturization and portability are also transforming the logistics of transplantation. Modern organ care devices are designed for intra-hospital, inter-city, and international transport, allowing broader access to high-quality organs and reducing wastage. Modular systems, battery operation, and cloud-based performance dashboards ensure safe and autonomous operation over long transit durations. Startups and research consortia are exploring closed-loop perfusion systems and perfusate reusability to reduce costs and streamline deployment in resource-constrained environments.

Which Stakeholders and Geographies Are Driving Adoption of Organ Care Technologies?

Adoption of organ care products is highest in regions with advanced transplant infrastructure, including North America, Western Europe, and select parts of Asia-Pacific. The U.S., UK, Germany, Canada, and Australia have emerged as early adopters of perfusion-based systems due to strong transplant programs, supportive regulatory frameworks, and availability of skilled personnel. Leading transplant centers and university hospitals in these regions are integrating organ care platforms into clinical protocols for heart, lung, and liver transplants.

The ecosystem includes transplant surgeons, perfusion technologists, procurement teams, and organ sharing networks who collaborate to optimize logistics and outcomes. Government agencies and nonprofit organizations like UNOS, NHS Blood and Transplant, and Eurotransplant play key roles in standardizing organ transport policies and co-funding technology trials. Commercial and research partnerships between med-tech firms, clinical institutions, and biobanks are further enhancing product development and clinical validation.

Emerging economies in Latin America, Eastern Europe, and the Middle East are beginning to explore organ care solutions to improve transplant access and reduce organ discard rates. However, high equipment costs and training gaps remain barriers to widespread adoption. Manufacturers are responding with scalable, modular designs and leasing models that make perfusion technology more accessible to mid-tier hospitals.

What Market Forces Are Accelerating the Growth and Innovation of Organ Care Products?

The growth in the global organ care products market is driven by several factors, including rising transplant volumes, greater organ scarcity, advancements in preservation science, and the push to expand donor eligibility. With the global transplant ecosystem strained by supply-demand mismatches and high post-transplant complication rates, organ care technologies offer a critical means to increase transplantable organ supply while ensuring better patient outcomes.

Regulatory endorsements and increasing reimbursement coverage are bolstering adoption. The FDA’s approval of the OCS Heart and Liver systems, for instance, has catalyzed procurement among top U.S. centers. Clinical guidelines now recommend machine perfusion for high-risk grafts, and payers are recognizing the long-term cost-effectiveness of reducing graft loss and hospital readmissions. Research grants and venture funding are accelerating the pipeline of next-generation devices, including xenotransplant-compatible platforms and integrated AI diagnostics.

Leading players like TransMedics, XVIVO Perfusion, OrganOx, Paragonix Technologies, and Bridge to Life are expanding product lines to support multiorgan compatibility, real-time monitoring, and simplified workflows. Cross-disciplinary innovation drawing from bioengineering, data science, and regenerative medicine is expected to push the frontier of organ care toward more personalized, predictive, and automated transplant logistics.

As organ demand continues to outpace availability, organ care products are set to become central enablers of transplant expansion, equity, and long-term success across the globe.